Prospective clinical trials with RIC HSCT in CLL: morbidity and mortality
| . | Dreger et al25,26 (N = 90) . | Sorror et al24 (N = 82) . | Brown et al27 (N = 76) . | Khouri et al35 (N = 86) . | Michallet et al79 (N = 40) . | Schetelig et al22 * (N = 30) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % . | Years . | % . | Years . | % . | Years . | % . | Years . | % . | Years . | % . | Years . | |
| Conditioning regimen | Nonmyeloablative (fludarabine-cyclophosphamide with/without anti-thymocyte globulin) | Nonmyeloablative (fludarabine, low-dose total body irradiation) | Reduced-intensity (fludarabine-busulfan) | Nonmyeloablative (fludarabine-cyclophosphamide-rituximab) | Nonmyeloablative (fludarabine-cyclophosphamide-rituximab) | Nonmyeloablative (fludarabine-busulfan) | ||||||
| Mucositis grade 3-4 | 6 | 12 | NR | NR | <5 | 23 | ||||||
| Infection grade 3-4 | 55 | 60 | NR | NR | 48 | NR | ||||||
| Early death (within 100 d from HSCT) | 2 | <10 | <3 | 3 | 0 | 7 | ||||||
| Nonrelapse mortality | 23 | 6 | 23 | 5 | 16 | 5 | 17 | 1 | 27 | 3 | 24 | 10 |
| Acute GVHD grade 3-4 | 14 | 16-23 | 17 | 7 | 23 | 20 | ||||||
| Extensive chronic GVHD | 55 | 49-53 | 48 | 56 | 29 | 21 | ||||||
| Follow-up, y | ||||||||||||
| Median | 6.0 | 5 | 5.1 | 3.1 | 2.3 | 10 | ||||||
| Range | 0.6-10.7 | 0.9-7.3 | 0.9-10.9 | 0.3-5.9 | ||||||||
| . | Dreger et al25,26 (N = 90) . | Sorror et al24 (N = 82) . | Brown et al27 (N = 76) . | Khouri et al35 (N = 86) . | Michallet et al79 (N = 40) . | Schetelig et al22 * (N = 30) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % . | Years . | % . | Years . | % . | Years . | % . | Years . | % . | Years . | % . | Years . | |
| Conditioning regimen | Nonmyeloablative (fludarabine-cyclophosphamide with/without anti-thymocyte globulin) | Nonmyeloablative (fludarabine, low-dose total body irradiation) | Reduced-intensity (fludarabine-busulfan) | Nonmyeloablative (fludarabine-cyclophosphamide-rituximab) | Nonmyeloablative (fludarabine-cyclophosphamide-rituximab) | Nonmyeloablative (fludarabine-busulfan) | ||||||
| Mucositis grade 3-4 | 6 | 12 | NR | NR | <5 | 23 | ||||||
| Infection grade 3-4 | 55 | 60 | NR | NR | 48 | NR | ||||||
| Early death (within 100 d from HSCT) | 2 | <10 | <3 | 3 | 0 | 7 | ||||||
| Nonrelapse mortality | 23 | 6 | 23 | 5 | 16 | 5 | 17 | 1 | 27 | 3 | 24 | 10 |
| Acute GVHD grade 3-4 | 14 | 16-23 | 17 | 7 | 23 | 20 | ||||||
| Extensive chronic GVHD | 55 | 49-53 | 48 | 56 | 29 | 21 | ||||||
| Follow-up, y | ||||||||||||
| Median | 6.0 | 5 | 5.1 | 3.1 | 2.3 | 10 | ||||||
| Range | 0.6-10.7 | 0.9-7.3 | 0.9-10.9 | 0.3-5.9 | ||||||||
J.S., unpublished observations.